|Articles|November 14, 2018
CSF-1 drops demonstrate efficacy, safety in clinical studies for treatment of presbyopia
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Advertisement
Elad Kedar, CEO of Orasis Pharmaceuticals, provides a company update at OIS@AAO 2018 in Chicago.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Spotlight on women's health: Understanding thyroid eye disease
2
FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report
3
NCX 470 advances toward US, China NDA submissions for NCX 470
4
Unmet Needs in Dry Eye Disease
5




































